Receive recommendations based on your profile and get approached by companies.

Logo AtriCure

AtriCure

Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 150,000 implanted to date.

Healthcare
Amsterdam, NL
750 employees

AtriCure

Share:

Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 150,000 implanted to date.

Healthcare
Amsterdam, NL
750 employees

Create a profile and get approached by companies that are interested in you.

5,000+ companies are sourcing actively.

Jobs

At this moment there are no open jobs at AtriCure.Please check again later.

Interesting to know

This company page was generated automatically and therefore features only limited information. Find out more about AtriCure on their company website:


This company page was generated automatically and therefore features only limited information. Find out more about AtriCure on their company website: